Orthofix (OFIX) AI Stock Analysis

• Market Cap: $482.32M
• Dividend Yield: N/A
• Average Volume (3M): 328.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: 4.84%
• EPS Growth: 0.85%
• Country: US
• Employees: 1,616
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Devices
• EPS (TTM): -0.36
• Shares Outstanding: 39,180,832
• 10 Day Avg. Volume: 343,618
• 30 Day Avg. Volume: 328,064
• PEG Ratio: 0.27
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 0.83
• P/FCF Ratio: -73.28
• Enterprise Value/Market Cap: 1.20
• Enterprise Value/Revenue: 0.71
• Enterprise Value/Gross Profit: 1.04
• Enterprise Value/Ebitda: -34.04
• 1Y Price Target: $21.00
• Price Target Upside: 70.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 55 Neutral
• Price Target: $13.00 ▲(5.61% Upside)

Orthofix's overall stock score is driven by strong earnings call performance and short-term technical momentum. However, significant challenges in financial performance and valuation, including negative profitability and cash flow constraints, weigh heavily on the score. The positive sentiment from recent earnings and strategic initiatives provides some optimism for future growth.

Positive Factors

Financial Performance

Orthofix is on the cusp of starting to generate consistent positive free cash flow, providing additional financial flexibility for internal investment, M&A opportunities, and potentially reducing debt.

Growth Drivers

The company's 7D Flash Navigation system is seen as a unique and differentiated growth driver.

Investment Potential

Analyst's recommendation is an OUTPERFORM investment rating with a 12-month price target of $16, suggesting a significant upside potential.

Negative Factors

Business Disruptions

There is a worry about the risk to long-range plan growth expectations due to disruptions from distributor upgrades.

Market Challenges

Orthofix experienced some softness in its US Spine Fixation and Biologics businesses as the company works to optimize its US Spine commercial channel.

Revenue Guidance

OFIX lowered its FY25 revenue guidance ~$10M to mainly account for lower-than-expected NGO business quarterly as well as distributor transition impacts in its US Spine business.

Orthofix Business Overview & Revenue Model

Company Description

Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

How the Company Makes Money

Orthofix generates revenue primarily through the sale of its orthopedic and spine products. The company's key revenue streams include sales of medical devices used in orthopedic reconstruction, regenerative tissue products, and bone growth therapies. Orthofix also earns income from its spine segment, which includes products like spinal implants and biologics. Significant partnerships with healthcare providers and distribution agreements further contribute to its revenue. The company's earnings are driven by product innovation, a robust distribution network, and its focus on expanding its market presence globally.

Orthofix Financial Statement Overview

Summary

Orthofix shows revenue growth and moderate leverage, but struggles with profitability and cash flow stability. Negative net profit margins and cash flow fluctuations highlight ongoing operational challenges.

Income Statement

Orthofix has shown consistent revenue growth with a 7.74% increase from 2023 to 2024. However, the company faces challenges with profitability, as evidenced by negative net profit margins and EBIT margins over the past years. The TTM data continues this trend with a further decline in profitability metrics, indicating ongoing operational struggles.

Balance Sheet

The company's balance sheet indicates a stable equity position with a debt-to-equity ratio of 0.42 in the TTM period, suggesting moderate leverage. However, the decline in stockholders' equity over time presents potential concerns. The equity ratio remains healthy, providing a cushion against liabilities.

Cash Flow

Orthofix's cash flow statement reveals fluctuations in free cash flow, with negative values indicating cash burn. The operating cash flow to net income ratio is positive, suggesting adequate cash generation relative to net losses, but the trend of negative free cash flow growth is a risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	809.03M	799.49M	746.64M	460.71M	464.48M	406.56M
Gross Profit	553.59M	545.88M	486.27M	337.17M	349.56M	304.67M
EBITDA	-16.93M	-34.18M	-86.98M	12.60M	17.94M	32.66M
Net Income	-123.71M	-126.00M	-151.40M	-19.75M	-38.38M	2.52M
Balance Sheet
Total Assets	837.16M	893.29M	925.32M	458.63M	476.62M	525.86M
Cash, Cash Equivalents and Short-Term Investments	65.61M	83.24M	33.11M	50.70M	87.85M	96.29M
Total Debt	175.29M	179.63M	134.20M	19.89M	22.48M	24.94M
Total Liabilities	378.81M	390.17M	326.58M	121.77M	139.69M	169.00M
Stockholders Equity	458.35M	503.12M	598.73M	336.86M	336.93M	356.86M
Cash Flow
Free Cash Flow	461.00K	-9.09M	-107.80M	-34.70M	-1.12M	57.18M
Operating Cash Flow	28.65M	25.79M	-45.75M	-11.54M	18.48M	74.27M
Investing Cash Flow	-20.83M	-27.58M	-33.13M	-24.53M	-23.01M	-52.33M
Financing Cash Flow	31.02M	50.71M	65.32M	-78.00K	-3.62M	3.25M

Orthofix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.31
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OFIX, the sentiment is Positive. The current price of 12.31 is above the 20-day moving average (MA) of 11.13, above the 50-day MA of 11.06, and below the 200-day MA of 15.22, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 65.09 is Neutral, neither overbought nor oversold. The STOCH value of 38.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OFIX.

Orthofix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIBN	61 Neutral	$681.83M	―	-14.18%	―	22.93%	43.83%
Sector *	60 Neutral	HK$17.54B	4.97	-4.95%	3.61%	9.71%	-38.85%
BVS	57 Neutral	$504.37M	―	-19.79%	―	8.60%	-42.76%
OFIX	55 Neutral	$482.32M	―	-24.63%	―	4.84%	0.85%
KIDS	50 Neutral	$500.09M	―	-11.49%	―	26.08%	-63.67%
AVNS	49 Neutral	$457.35M	45.80	-46.17%	―	1.34%	-530.36%
TMCI	40 Underperform	$351.64M	―	-45.73%	―	7.54%	4.28%

Orthofix Corporate Events

Orthofix Reports Q2 2025 Financial Results and Growth

Orthofix Medical Inc. reported its financial results for the second quarter of 2025, showing net sales of $203.1 million, a 2% increase from the previous year, and a net loss of $14.1 million. The company highlighted significant growth in U.S. Spine Fixation and Bone Growth Therapies, as well as the launch of new products like the TrueLok Elevate Transverse Bone Transport System and the Reef L Interbody System. Orthofix’s strategic initiatives, including distributor transitions, have led to a positive free cash flow and an increase in adjusted EBITDA margin, positioning the company for sustainable growth and long-term shareholder value.

The most recent analyst rating on (OFIX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Orthofix stock, see the OFIX Stock Forecast page.

Orthofix Shareholders Meeting and Board Elections

On June 18, 2025, Orthofix Medical Inc. held its annual meeting of shareholders, where a quorum was achieved with 35,364,307 shares present. Key decisions included the election of the board of directors for a one-year term, approval of executive compensation, and ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year 2025. Additionally, Vickie L. Capps was appointed to the Audit and Finance Committee and the Compensation and Talent Development Committee, effective immediately.

The most recent analyst rating on (OFIX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Orthofix stock, see the OFIX Stock Forecast page.